Margaret M Mroz1, John H Ferguson2, Anna V Faino2, Annyce Mayer2, Matthew Strand2, Lisa A Maier3. 1. National Jewish Health, Department of Medicine, 1400 Jackson Street, Denver, CO 80206, United States. 2. National Jewish Health, Department of Medicine, 1400 Jackson Street, Denver, CO 80206, United States; Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 13001 E. 17th Pl., Aurora, CO 80045, United States. 3. National Jewish Health, Department of Medicine, 1400 Jackson Street, Denver, CO 80206, United States; Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 13001 E. 17th Pl., Aurora, CO 80045, United States; Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Pl., Aurora, CO 80045, United States. Electronic address: Maierl@njhealth.org.
Abstract
BACKGROUND: The clinical effects of inhaled corticosteroids (ICS) on chronic beryllium disease (CBD) are unknown. Although frequently used for symptoms or disease not requiring systemic therapy, the clinical course of patients on ICS has not been evaluated. METHODS: In a retrospective cohort study, forty-eight subjects with CBD, diagnosed by granulomas on lung biopsy and treated with inhaled corticosteroids, were matched to sixty-eight subjects with CBD who were not treated. Pulmonary function testing, exercise tolerance, blood BeLPT, BAL cell count, and symptoms were evaluated. RESULTS: Treated patients showed no significant change over time in pulmonary function, when compared to controls, by forced vital capacity (FVC, p = 0.28) or diffusion capacity (DLCO, p = 0.45) or in exercise tolerance testing. However, symptoms of cough significantly improved in 58% (compared to 17% in controls) and dyspnea improved in 26% after ICS treatment (compared to 0 in controls). Symptoms of cough were improved in patients with a lower baseline FEV1 and FEV1/FVC ratio. Subgroup analysis showed significant lung function response in cases with lower baseline FEV1/FVC and higher residual volume (RV). CONCLUSION: Although FVC and DLCO did not improve in the ICS treated group, we saw no difference in decline compared to matched controls. Symptoms of dyspnea and cough improved with ICS especially in those with obstruction and air trapping suggesting that these should be considered an indication of ICS use in CBD patients.
BACKGROUND: The clinical effects of inhaled corticosteroids (ICS) on chronic beryllium disease (CBD) are unknown. Although frequently used for symptoms or disease not requiring systemic therapy, the clinical course of patients on ICS has not been evaluated. METHODS: In a retrospective cohort study, forty-eight subjects with CBD, diagnosed by granulomas on lung biopsy and treated with inhaled corticosteroids, were matched to sixty-eight subjects with CBD who were not treated. Pulmonary function testing, exercise tolerance, blood BeLPT, BAL cell count, and symptoms were evaluated. RESULTS: Treated patients showed no significant change over time in pulmonary function, when compared to controls, by forced vital capacity (FVC, p = 0.28) or diffusion capacity (DLCO, p = 0.45) or in exercise tolerance testing. However, symptoms of cough significantly improved in 58% (compared to 17% in controls) and dyspnea improved in 26% after ICS treatment (compared to 0 in controls). Symptoms of cough were improved in patients with a lower baseline FEV1 and FEV1/FVC ratio. Subgroup analysis showed significant lung function response in cases with lower baseline FEV1/FVC and higher residual volume (RV). CONCLUSION: Although FVC and DLCO did not improve in the ICS treated group, we saw no difference in decline compared to matched controls. Symptoms of dyspnea and cough improved with ICS especially in those with obstruction and air trapping suggesting that these should be considered an indication of ICS use in CBDpatients.
Authors: John R Balmes; Jerrold L Abraham; Raed A Dweik; Elizabeth Fireman; Andrew P Fontenot; Lisa A Maier; Joachim Muller-Quernheim; Gaston Ostiguy; Lewis D Pepper; Cesare Saltini; Christine R Schuler; Tim K Takaro; Paul F Wambach Journal: Am J Respir Crit Care Med Date: 2014-11-15 Impact factor: 21.405
Authors: T Handa; S Nagai; M Kitaichi; K Chin; Y Ito; T Oga; K Takahashi; K Watanabe; M Mishima; T Izumi Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2009-07 Impact factor: 0.670
Authors: Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot Journal: Respir Med Date: 2012-09-11 Impact factor: 3.415
Authors: S Marchand-Adam; A El Khatib; F Guillon; M W Brauner; C Lamberto; V Lepage; J-M Naccache; D Valeyre Journal: Eur Respir J Date: 2008-09 Impact factor: 16.671